52 Biotechnology Stocks to Sell Now

52 Biotechnology Stocks to Sell Now

The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Amgen Inc. (AMGN) experiences a ratings drop this week, going from last week’s C to a D. Amgen Inc. discovers, develops, manufactures, and markets medicines for serious illnesses. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

This is a rough week for United Therapeutics Corporation (UTHR). The company’s rating falls to D from the previous week’s C. United Therapeutics Corporation is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of UTHR stock.

AbbVie, Inc. (ABBV) earns a D this week, moving down from last week’s grade of B. AbbVie, Inc. a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Alkermes Plc (ALKS) gets weaker ratings this week as last week’s C drops to a D. Alkermes Plc is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of ALKS stock.

Slipping from a C to a D rating, Prothena Corp. Plc (PRTA) takes a hit this week. The company also gets F’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of PRTA stock.

Neurocrine Biosciences, Inc.’s (NBIX) rating weakens this week, dropping to a D versus last week’s C. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

Alnylam Pharmaceuticals, Inc (ALNY) slips from a D to a F this week. Alnylam Pharmaceuticals, Inc engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

Acceleron Pharma Inc (XLRN) declines this week from a C to a D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of XLRN stock.

This week, Ionis Pharmaceuticals, Inc.’s (IONS) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of IONS stock.

Emergent BioSolutions Inc. (EBS) is having a tough week. The company’s rating falls from a C to a D. Emergent BioSolutions Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of EBS stock.

This week, Enanta Pharmaceuticals, Inc. (ENTA) drops from a C to a D rating. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENTA stock.

This week, MacroGenics, Inc.’s (MGNX) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in operating margin growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of MGNX stock.

Cellectis SA Sponsored ADR (CLLS) declines this week from a C to a D. For more information, get Portfolio Grader’s complete analysis of CLLS stock.

Myriad Genetics, Inc. (MYGN) slips from a D to a F this week. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. The company also gets F’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MYGN stock.

FibroGen, Inc. (FGEN) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of FGEN stock.

This week, Heron Therapeutics Inc (HRTX) drops from a D to a F rating. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HRTX stock.

Slipping from a C to a D rating, Axovant Sciences Ltd (AXON) takes a hit this week. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of AXON stock.

Momenta Pharmaceuticals, Inc.’s (MNTA) rating weakens this week, dropping to a F versus last week’s D. Momenta Pharmaceuticals, Inc. is a biotechnology company which specializes in sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MNTA stock.

This is a rough week for Insys Therapeutics, Inc. (INSY). The company’s rating falls to F from the previous week’s D. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in sales growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Dynavax Technologies Corporation (DVAX) experiences a ratings drop this week, going from last week’s D to a F. Dynavax Technologies Corporation discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DVAX stock.

Xenon Pharmaceuticals Inc. (XENE) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of XENE stock.

Trillium Therapeutics Inc. (TRIL) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRIL stock.

Amicus Therapeutics, Inc. (FOLD) experiences a ratings drop this week, going from last week’s C to a D. Amicus Therapeutics, Inc. is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FOLD stock.

This week, NantKwest, Inc.’s (NK) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NK stock.

ZIOPHARM Oncology, Inc. (ZIOP) gets weaker ratings this week as last week’s D drops to a F. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

This week, Aldeyra Therapeutics, Inc. (ALDX) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

Nivalis Therapeutics, Inc. (NVLS) is having a tough week. The company’s rating falls from a C to a D. Nivalis Therapeutics, Inc. manufactures, sells, and supports equipment used in the fabrication of chips and semiconductors. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVLS stock.

ImmuCell Corporation (ICCC) slips from a C to a D this week. ImmuCell Corporation is engaged in the development, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industry. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ICCC stock.

PTC Therapeutics, Inc. (PTCT) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTCT stock.

This is a rough week for Sorrento Therapeutics, Inc. (SRNE). The company’s rating falls to F from the previous week’s D. The company also gets F’s in sales growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SRNE stock.

Slipping from a C to a D rating, vTv Therapeutics, Inc. Class A (VTVT) takes a hit this week. The company also gets F’s in earnings momentum and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTVT stock.

Synergy Pharmaceuticals, Inc. (SGYP) earns a D this week, moving down from last week’s grade of C. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Achillion Pharmaceuticals, Inc.’s (ACHN) rating weakens this week, dropping to a F versus last week’s D. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Ignyta, Inc. (RXDX) declines this week from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXDX stock.

This week, Adaptimmune Therapeutics PLC Sponsored ADR’s (ADAP) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

Agenus Inc.’s (AGEN) rating weakens this week, dropping to a D versus last week’s C. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

This is a rough week for Cyclacel Pharmaceuticals, Inc. (CYCC). The company’s rating falls to D from the previous week’s C. Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CYCC stock.

Slipping from a C to a D rating, Genocea Biosciences, Inc. (GNCA) takes a hit this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

Asterias Biotherapeutics Inc Class A (AST) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AST stock.

Dicerna Pharmaceuticals, Inc. (DRNA) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRNA stock.

Capricor Therapeutics, Inc. (CAPR) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of CAPR stock.

Vical Incorporated (VICL) is having a tough week. The company’s rating falls from a D to a F. Vical Incorporated researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

This week, Fortress Biotech, Inc. (FBIO) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FBIO stock.

Stellar Biotechnologies, Inc. (SBOT) slips from a D to a F this week. The company also gets F’s in earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SBOT stock.

Fate Therapeutics, Inc. (FATE) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FATE stock.

QLT Inc. (QLTI) is having a tough week. The company’s rating falls from a C to a D. QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of QLTI stock.

Windtree Therapeutics, Inc. (WINT) declines this week from a C to a D. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of WINT stock.

Conatus Pharmaceuticals Inc. (CNAT) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

This is a rough week for MEI Pharma, Inc. (MEIP). The company’s rating falls to D from the previous week’s C. MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MEIP stock.

Pieris Pharmaceuticals, Inc. (PIRS) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PIRS stock.

This week, ArQule, Inc. (ARQL) drops from a D to a F rating. ArQule, Inc. is a biotechnology company that is engaged in the research and development of cancer therapeutics. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

Aptose Biosciences Inc. (APTO) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APTO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/52-biotechnology-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC